Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduc	ction Act of 1995, no bersons	are required to respond to a coll	COUCH OF HIME		
		Application Number	10/580,94	10	
O YRANSM	ITTAL	Filing Date	30 May 2	006	
FOR		First Named Inventor	John C. L	ANG	
OCT 0 5 2006	•••	Art Unit .			
13 44/		Examiner Name			
be used for all correspond	dence after initial filing)	Attorney Docket Number	2668 US	F	
Total Number of Pages in This	s Submission		2000 00	<u>'</u>	
	ENC	LOSURES (Check all	that apply)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/dec Extension of Time Re Express Abandonme Information Disclosu Certified Copy of Pridocument(s)	claration(s) equest ent Request re Statement	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatio Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Clarks	Address	Appea of App Appea (Appea Proprie Status Other below	Illowance Communication to TC I Communication to Board eals and Interferences I Communication to TC I Notice, Brief, Reply Brief) etary Information Letter Enclosure(s) (please Identify): eferences and Return Card.
Reply to Missing Pai Incomplete Applicati Reply to Missing Pai under 37 CF	on sing Parts R 1.52 or 1.53	OF APPLICANT, ATTO	ORNEY, C	OR AGENT	
Firm Name		. Alcon Rese	arch, Ltd.		
Signature		Joreph Mly	£,		
Printed name		Teresa J.	Schultz ·		
Date			Reg. No.		40,526
I hereby certify that this cor sufficient postage as first cl the date shown below:		ICATE OF TRANSMISS simile transmitted to the USP addressed to: Commissioner f	TO or deno	sited with the U P.O. Box 1450	Inited States Postal Service with Alexandria, VA 22313-1450 on
Signature	Bar	Dara M	6K	enra	ب
Typed or printed name		Barbara McKenzie		Date	25 September 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John C.

Serial No: 10/580,940

Filed: 30 May 2006

Examiner:

Group Art Unit: 1615

•

COMPOSITION AND METHODS FOR INHIBITING THE PROGRESSION MACULAR DEGENERATION AND PROMOTING HEALTHY VISION

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2), copies of the U.S. patent applications are <u>not</u> enclosed.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

 $\mathbf{R}\mathbf{v}$

By:

Teresa J. Schultz Registration No. 40,256

(817) 551-4231

Address for Correspondence:
Alcon Research, Ltd.
Attn: Teresa J. Schultz
6201 S. Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099
Attorney Docket No.: 2668 US F

Date

PTO/SB/08A (07-06)

Approved for use through 09/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number. OCT 0 a 2005 ersons are required

Under the Paperwork Reduction Act of 1995, no

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Coi	mplete if Known
Application Number	10/580,940
Filing Date	30 May 2006
First Named Inventor	John C. LANG
Art Unit	
Examiner Name	
Attorney Docket Number	2668 US F

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1A	US- 2002/182266 A1	12-05-2002	Bartels et al.	
	1B	^{US-} 2003/0064133	04-03-2003	Blatt et al.	
	1C	^{US-} 3,998,753	12-21-1976	Antoshkiw et al.	
	1D	^{US-} 4,254,100	03-03-1981	Keller et al.	
	1E	^{US-} 4,657,928	04-14-1987	Sorenson	
	1F	^{US-} 4,670,247	06-02-1987	Scialpi	
	1G	^{US-} 6,582,721	06-24-2003	Lang	
	1H	^{US-} 6,649,195	11-18-2003	Gorsek	
		US-			
		US-		·	
		US-			
	 	US-			

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
	1H	DE 101 09 798 A1	09-12-2002	Aventis Pharma		
	11	WO 2005/065669 A1	07-21-2005	Alcon, Inc.		
						-
	ļ					╁
						-

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Ρ	TC)/S	B/0	8B	(0	7-06

Approved for use through 09/30/2006. OMB 051-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitut	e for form 1449/PTO	3	OCT 0 5 7006 &	Application Number	10/580,940
INFO	ORMATION	I D	CLOSURE PLEMOWNT	Filing Date	30 May 2006
STA	TEMENT E	BY A	PENGANT	First Named Inventor	John C. LANG
				Art Unit	
	(Use as many sho	eets as n	ecessary)	Examiner Name	
Sheet	2	of	5	Attorney Docket Number	2668 US F

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2A	AREDS Report No. 9, Age-Related Eye Disease Study Research Group: "A Randomized, Placebo-Controlled, Clinical Trial Of High-Dose Supplementation With Vitamins C And E And Beta Carotene For Age-Related Cataract And Vision Loss", Archives Of Ophthalmology, 119(10):1439-1452 (2001)	
	2B	BEEM, J BIOL CHEM 249:7298 (1974)	
	2C	BERMAN, BIOCHEMISTRY OF THE EYE, (Plenum Press, 1991), 309-330, 345-359 and 386-399	
	2D	BERNSTEIN et al., Retinal Tubulin Binds Macular Carotenoids, INV OPHTHAL & VIS SCI 38(1):167-175 (1997)	
	2E	BONE and LANDRUM, AM SOCIETY FOR NUTRITIONAL SCIENCES J NUTR, 133:992-998 (2003)	1
	2F	CHANDLER et al., J. BIOL. CHEM 261:928-33 (1986)	
	2G	CHANEY, TEXTBOOK OF BIOCHEMISTRY WITH CLINICAL CORRELATIONS, John Wiley & Sons, 970-971 (1986)	
	2H	CHATTERJEE and GHOSH, ARCH, OPHTHALMOL 56:756-60 (1956)	
	21	FISCHER, J NUTRITION 113:462-469 (1983)	
	2J	HAMMOND et al., Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns, VISION RESEARCH 36:2001-2012 (1996a)	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO	Idelion Ac	or 1000, no polastia al		Complete if Known
Substitut	te 101 101111 1449/P10			Application Number	10/580,940
INFO	ORMATION	I DIS	CLOSURE	Filing Date	30 May 2006
STA	TEMENT E	BY AF	PPLICANT	First Named Inventor	John C. LANG
				Art Unit	
	(Use as many she	eets as ne	ecessary)	Examiner Name	
Sheet	3	of	5	Attorney Docket Number	2668 US F

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	ЗА	HAMMOND et al., Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration, VISION RESEARCH 36:3003-3009 (1996b)	
	3B	HAMMOND et al., Dietary Modification of Human Macular Pigment Density, INV OPHTHAL & VIS SCI 38 (9):1795-1801 (1997)	
	3C	HANDELMAN et al., Biological Control of Primate Macular Pigment: Biochemical and Densitometric Studies, INV OPHTHAL & VIS SCI 32(2):257-267 (1991)	
	3D	HARRIS, NATURE 132:27-8 (1993)	
	3E	HOOPER et al., JAMA 244:1960-1961 (1980)	
	3F	JACQUES et al., Antioxidant Status in Persons With and Without Senile Cataract, ARCH. OPHTHALM. 106:337-340 (1988)	
···········	3G	KARCIOGLU, SURV OPHTHALMOL 27:114-122 (1982)	
	зн	LEURE-DUPREE, RETINA 2:294-302 (1982a)	
	311	LEURE-DUPREE, INVEST OPHTHALMOL VIS SCI 23:425-34 (1982b)	
	3J	MACHLIN et al., Free Radical Tissue Damage: Protective Role of Antioxidant Nutrients, FASEB J 1:441-445 (1987)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond

Substitu	ite for form 1449/PTC)		The second secon	Complete if Known	ntroi number.
				Application Number	10/580,940	
			CLOSURE	Filing Date	30 May 2006	
STATEMENT BY APPLICANT				First Named Inventor	John C. LANG	
İ	(Use as many si	heets as n	oressanv)	Art Unit		
				Examiner Name		
Sheet	4	of	5	Attorney Docket Number	2668 US F	
					<u> </u>	

NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (heal magning in the item)).					
Initials*	No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	4A	MANSOUR et al., Effect Of Antioxidant (Vitamin E) On The Progress Of Cataracts In Emory Mice, ARVO Abstract #47, pg 138 (1984 Supplement)			
	4B	NEWSOME, D.A., Oral Zinc in Macular Degeneration, ARCH. OPHTHALMOL. 106:192-198 (1988)			
	4C	OHRLOFF and HOCKWIN, GRAEFE'S ARCH CLIN EXP OPHTHALMOL 222:79-81 (1984)			
	4D	ORTEN, HUMAN BIOCHEMISTRY 10th Edition, CV Mosby Co., p. 756-757 (1982)			
	4E	PCT International Search Report of the related PCT Application No. PCT/US2004/041813, mailed June 13, 2005			
	4F	PENNINGTON, J AM DIETETIC ASSOC 86:876-91 (1986)			
	4G	PURCELL et al., ARCH OPHTHALMOL 51:1-6 (1968)			
	4H	RINGVOLD, ACTA, OPHTHALMOLOGICA 63:227-2 80 (1985)			
	41	RUSSELL, ANN INT MED 99:227-239 (1983)			
	4J	SEDDON et al., Dietary Carotenoids, Vitamins A, C and E, and Advanced Age-Related Macular Degeneration, JAMA 272(8):1413-1420 (1994)			

F Total Williams	
Examiner	Date
	Date
Signature	Compilered
o.gataro	Considered
	A 100 Annual Control (A) 271 (A) 144

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/580,940	
			CLOSURE	Filing Date	30 May 2006	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	John C. LANG	
	(Use as many sh	noote se n	ecossan/)	Art Unit		
	(Ose as many sn	reeta da m	ecessury	Examiner Name		
Sheet	5	of	5	Attorney Docket Number	2668 US F	

Evaminer	Cito	NON PATENT LITERATURE DOCUMENTS	ı
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	5A	SNODDERLY, Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins, AM J CLIN NUTR 62(suppl):1448S-1461S (1995)	
	5B	SPARROW et al., 2001, Bioorganic & Medicinal Chemistry Letters, 11, 1533-1540	
	5C	SPECTOR et al., EXP. EYE RES. 33:673-681 (1981)	
·	5D	SWANSON, BIOCHEM BIPHY RES COMM 45:1488-1496 (1971)	
	5E	VAN CAMPEN, J NUTRITION 97:104-108 (1970)	
	5F	VARMA et al., OPHTHALMIC RES 9:421-431 (1977)	
	5G	VARMA et al., OPHTHALMIC RES 26:141-148 (1994)	
	5H	WAGNER, GERIATRICS 40:111-125 (1985)	
	51	WILLIAMS, PEDIAT RES 1:823-826 (1977)	
	5J		

Evaminar	D-4-	
Examiner	Date	I
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).
2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.